english.prescrire.org > Spotlight > Archives : 2017 > Prescrire's ratings: new products and indications over the last 10 years

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2017 : 1 | 30 | 60

Prescrire's ratings: new products and indications over the last 10 years

Each spring, Prescrire International publishes a recap of the drugs reviewed in our French edition during the previous year. It includes a table summing up the ratings Prescrire's editors gave to the new drugs and indications reviewed during each of the past ten years.

 
 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Bravo  BRAVO
1 0 0 0 0 0 0 1 0 0
A Real Advance  A REAL ADVANCE
2 0 0 1 0 1 0 2 3 1(b)
Offers an advantage  OFFERS AN ADVANTAGE
14 6 3 3 3 3 6 5 5 5(c)
Possibly helpful  POSSIBLY HELPFUL
27 25 14 22 13 14 12 15 15 9
Nothing new  NOTHING NEW
79 57 62 49 53 42 48 35 43 56
Not acceptable  NOT ACCEPTABLE
15 23 19 19 16 15 15 19 15 16(d)
Judgement reserved  JUDGEMENT RESERVED
3 9 6 3 7 7 9 10 6 5(e)
TOTAL 141 120 104 97 92 82 90 87 87 92
See: the
year in
review		 2007
(pdf)		 2008
(pdf)		 2009
(pdf)		 2010
(pdf)		 2011
(pdf)		 2012
(pdf)		  2013
(pdf)		 2014
(pdf)		 2015
(pdf)		 2016
(pdf)
For details on these categories, see: > Prescrire's drug ratings


a- About this table

This table includes new products (other than generics) and new indications, as well as products re-examined after longer follow-up.
For prior years (in French, subscription to French edition required):  > 1981-2000, > 1992-2006

b- The only drug rated "A REAL ADVANCE" in 2016 was:

  • nivolumab in metastatic or inoperable BRAF V600 mutation-negative melanoma
    (Prescrire Int n° 177).

c- The drugs rated "OFFERS AN ADVANTAGE" in 2016 were:

  • dexamethasone 40 mg in multiple myeloma (Rev Prescrire n° 395);
  • entecavir in chronic hepatitis B in children (Prescrire Int n° 179);
  • nivolumab in certain types of metastatic or inoperable lung cancer (Rev Prescrire n° 397);
  • succimer 100 mg in lead or mercury poisoning (Rev Prescrire n° 392);
  • trametinib in metastatic or inoperable BRAF V600 mutation-positive melanoma
    (Prescrire Int n° 177).

d- The drugs rated "NOT ACCEPTABLE" in 2016 were:

  • adalimumab in hidradenitis suppurativa (Prescrire Int n° 181);
  • capsaicin in painful diabetic neuropathy (Prescrire Int n° 180);
  • ceritinib in certain types of non-small cell lung cancer (Prescrire Int n° 174);
  • ciclosporin eye drops in dry eye disease (Prescrire Int n° 181);
  • the estradiol + dydrogesterone 0.5 mg/2.5 mg combination in postmenopausal hormone replacement therapy (Rev Prescrire n° 388);
  • febuxostat in hyperuricaemia associated with tumour lysis syndrome (Prescrire Int n° 173);
  • idebenone in Leber’s hereditary optic neuropathy (Prescrire Int n° 179);
  • the insulin degludec + liraglutide combination in type 2 diabetes (see page 121);
  • mepolizumab in severe refractory asthma (Prescrire Int n° 179);
  • nintedanib in certain types of inoperable non-small cell lung cancer (Rev Prescrire n° 389);
  • nintedanib in idiopathic pulmonary fibrosis (Prescrire Int n° 173);
  • olaparib in certain types of ovarian cancer (Prescrire Int n° 178);
  • panobinostat in multiple myeloma (Prescrire Int n° 176);
  • prucalopride in chronic constipation in men (Prescrire Int n° 175);
  • the simvastatin + fenofibrate combination in hypercholesterolaemia and hypertriglyceridaemia (Prescrire Int n° 173);
  • tigecycline in serious infections in children (Prescrire Int n° 173).

e- The drugs rated "JUDGEMENT RESERVED" in 2016 were:

  • denosumab in giant cell tumour of bone (Rev Prescrire n° 388);
  • empagliflozin, alone or combined with metformin in type 2 diabetes (Prescrire Int n° 172);
  • ibrutinib in chronic lymphocytic leukaemia and mantle cell lymphoma (Prescrire Int n° 170);
  • lenvatinib in differentiated thyroid carcinoma (Rev Prescrire n° 398);
  • the RTS,S/AS01E malaria vaccine for immunisation of children against malaria and hepatitis B (Prescrire Int n° 178).

©Prescrire 1 May 2017

"New products and new indications in 2016: a system that favours imitation over the pursuit of real progress" Prescrire Int 2017; 26 (182): 136-139. (Pdf, free)
Download the full review.
Pdf, free

For more information:

The year in review: New drugs
and new indications in 2016
(May 2016)
Free

Prescrire's drug ratings
(February 2017)
Free